SG11202003178PA - Btk inhibitor compounds - Google Patents

Btk inhibitor compounds

Info

Publication number
SG11202003178PA
SG11202003178PA SG11202003178PA SG11202003178PA SG11202003178PA SG 11202003178P A SG11202003178P A SG 11202003178PA SG 11202003178P A SG11202003178P A SG 11202003178PA SG 11202003178P A SG11202003178P A SG 11202003178PA SG 11202003178P A SG11202003178P A SG 11202003178PA
Authority
SG
Singapore
Prior art keywords
btk inhibitor
inhibitor compounds
compounds
btk
inhibitor
Prior art date
Application number
SG11202003178PA
Other languages
English (en)
Inventor
Kenneth James Henry
Albert Khilevich
Steven Kuklish
Katherine Partridge
Steven Quimby
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11202003178PA publication Critical patent/SG11202003178PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202003178PA 2017-11-06 2018-10-30 Btk inhibitor compounds SG11202003178PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581967P 2017-11-06 2017-11-06
PCT/US2018/058104 WO2019089512A1 (en) 2017-11-06 2018-10-30 Btk inhibitor compounds

Publications (1)

Publication Number Publication Date
SG11202003178PA true SG11202003178PA (en) 2020-05-28

Family

ID=64277913

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003178PA SG11202003178PA (en) 2017-11-06 2018-10-30 Btk inhibitor compounds

Country Status (34)

Country Link
US (1) US11542249B2 (ar)
EP (1) EP3707133B1 (ar)
JP (1) JP6920553B2 (ar)
KR (1) KR102410202B1 (ar)
CN (1) CN111278818B (ar)
AR (1) AR113796A1 (ar)
AU (1) AU2018360478B2 (ar)
BR (1) BR112020006749A2 (ar)
CA (1) CA3080123C (ar)
CL (1) CL2020001089A1 (ar)
CR (1) CR20200183A (ar)
CY (1) CY1124994T1 (ar)
DK (1) DK3707133T3 (ar)
DO (1) DOP2020000103A (ar)
EA (1) EA039398B1 (ar)
EC (1) ECSP20024395A (ar)
ES (1) ES2904843T3 (ar)
HR (1) HRP20220178T1 (ar)
HU (1) HUE057987T2 (ar)
IL (1) IL273778B (ar)
JO (1) JOP20200104A1 (ar)
LT (1) LT3707133T (ar)
MA (1) MA50561B1 (ar)
MD (1) MD3707133T2 (ar)
MX (1) MX2020004435A (ar)
PE (1) PE20201168A1 (ar)
PL (1) PL3707133T3 (ar)
PT (1) PT3707133T (ar)
RS (1) RS62805B1 (ar)
SG (1) SG11202003178PA (ar)
SI (1) SI3707133T1 (ar)
TW (1) TWI694995B (ar)
UA (1) UA126079C2 (ar)
WO (1) WO2019089512A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220011652A (ko) * 2019-05-23 2022-01-28 노파르티스 아게 브루톤 타이로신 키나제 저해제를 사용하여 쇼그렌 증후군을 치료하는 방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2426109B1 (en) * 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Novel kinase inhibitors
RU2617405C2 (ru) * 2010-05-07 2017-04-25 Джилид Коннектикут, Инк. Пиридоновые и азапиридоновые соединения и способы применения
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
SG10201604682VA (en) * 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
WO2014093230A2 (en) * 2012-12-10 2014-06-19 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2017059280A1 (en) * 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors

Also Published As

Publication number Publication date
AU2018360478A1 (en) 2020-04-23
BR112020006749A2 (pt) 2020-10-06
AR113796A1 (es) 2020-06-10
EA039398B1 (ru) 2022-01-24
MD3707133T2 (ro) 2022-07-31
MA50561B1 (fr) 2022-03-31
IL273778B (en) 2022-06-01
ES2904843T3 (es) 2022-04-06
EP3707133A1 (en) 2020-09-16
AU2018360478B2 (en) 2020-09-17
DK3707133T3 (da) 2022-01-03
MA50561A (fr) 2020-09-16
CA3080123C (en) 2021-11-09
EP3707133B1 (en) 2021-12-15
TWI694995B (zh) 2020-06-01
CL2020001089A1 (es) 2020-10-23
MX2020004435A (es) 2020-08-06
CY1124994T1 (el) 2023-01-05
JOP20200104A1 (ar) 2022-10-30
IL273778A (en) 2020-05-31
ECSP20024395A (es) 2020-06-30
HUE057987T2 (hu) 2022-06-28
CN111278818B (zh) 2023-03-28
LT3707133T (lt) 2022-01-25
JP2021501749A (ja) 2021-01-21
NZ764452A (en) 2023-09-29
TW201930293A (zh) 2019-08-01
PE20201168A1 (es) 2020-10-28
CA3080123A1 (en) 2019-05-09
SI3707133T1 (sl) 2022-02-28
HRP20220178T1 (hr) 2022-04-29
US11542249B2 (en) 2023-01-03
KR20200060480A (ko) 2020-05-29
CR20200183A (es) 2020-05-30
PT3707133T (pt) 2022-01-27
EA202090843A1 (ru) 2020-07-24
US20200290997A1 (en) 2020-09-17
KR102410202B1 (ko) 2022-06-22
PL3707133T3 (pl) 2022-04-04
DOP2020000103A (es) 2020-09-15
WO2019089512A1 (en) 2019-05-09
UA126079C2 (uk) 2022-08-10
RS62805B1 (sr) 2022-02-28
JP6920553B2 (ja) 2021-08-18
CN111278818A (zh) 2020-06-12

Similar Documents

Publication Publication Date Title
IL268282B (en) hiv inhibitory compounds
IL269196A (en) New inhibitors
EP3246317A4 (en) Btk inhibitor
GB201700814D0 (en) Compounds
GB201705971D0 (en) Inhibitor compounds
GB201403536D0 (en) Inhibitor compounds
HK1247607A1 (zh) P62-zz化學抑制劑
GB201513481D0 (en) Inhibitor compounds
GB201505658D0 (en) Inhibitor compounds
SG11202005870RA (en) Novel mtor inhibitor compounds
IL292485B1 (en) Pyridylpyridone compounds
IL273778B (en) Compounds of btk inhibitors
GB201702221D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201720145D0 (en) Inhibitor compounds
GB201708507D0 (en) Inhibitor compounds
GB201708510D0 (en) Inhibitor compounds
GB201708502D0 (en) Inhibitor compounds
GB201705968D0 (en) Inhibitor compounds
GB201621619D0 (en) Inhibitor compounds
GB201717530D0 (en) New compounds
GB201717050D0 (en) Compounds
GB201714049D0 (en) New compounds
GB201712289D0 (en) New compounds
GB201707966D0 (en) Compounds